A new method of harvesting stem cells for bone marrow transplantation – developed by a team of investigators from the Massachusetts General Hospital (MGH) Cancer Center and the Harvard Stem Cell Institute – appears to accomplish two goals: making the donation process more convenient and less unpleasant for donors and providing cells that are superior to those acquired by current protocols. Results of the team’s studies in animal models and humans will appear in the Jan. 11 issue of Cell and are being published online today.
“Our new method of harvesting stem cells requires only a single injection and mobilizes the cells needed in 15 minutes; so in the time it takes to boil an egg, we are able to acquire the number of stem cells produced by the current standard five-day protocol,” says Jonathan Hoggatt, PhD, of the MGH Cancer Center)and Center for Transplantation Sciences, lead author of the Cell paper. “This means less pain, time off work and lifestyle disruption for the donor; more convenience for the clinical staff, and more predictability for the harvesting procedure.”
Currently, the most common way of harvesting hematopoietic (blood system) stem cells requires donors to receive daily injections of a drug called G-CSF, which induces stem cells to pass from the bone marrow into the circulation. After five days of injections – which can produce adverse effects ranging from bone pain, to nausea and vomiting, to enlargement or rupture of the spleen – the stem cells are collected through the bone marrow donation process of apheresis, which takes four to five hours. Sometimes more than one apheresis is required to collect enough stem cells, particularly when patients with conditions like multiple myeloma or non-Hodgkin’s lymphoma are donating their own cells.
Hoggatt and colleagues at MGH and other institutions have investigated ways to enhance stem cell donation for several years. In a previous collaboration with Louis Pelus, PhD, of Indiana University School of Medicine , senior author of the current study, they found that adding NSAID drugs like aspirin or ibuprofen could double the effectiveness of the standard collection protocol. But since that approach still relied on multiple injections of G-CSF, the team determined that truly significant improvement to stem cell donation required eliminating the need for G-CSF.
In other previous work, Pelus’s team had found that a protein called GRO (growth regulated oncogene)-beta induced rapid movement of stem cells from the marrow into the blood in animal models. Initial experiments by the current study’s team revealed that GRO-beta injections were safe and well tolerated in human volunteers but had only a modest effect in mobilizing stem cells. As a result, they tried combining administration of GRO-beta with AMD3100, a drug that is already approved to increase stem cell mobilization in combination with G-CSF, and found that simultaneous administration of both drugs rapidly produced a quantity of cells equal to that provided by the five-day G-CSF protocol.
In addition to determining the mechanisms by which combined administration of GRO-beta and AMD3100 produced enough stem cells so quickly, the team found that transplantation with these cells led to faster reconstitution of bone marrow and recovery of immune cell populations in mouse models. The stem cells produced by this procedure also show patterns of gene expression similar to those of fetal hematopoietic stem cells (HSCs), which are located in the liver, rather than the bone marrow.
“These highly engraftable hematopoietic stem cells produced by our new strategy are essentially the A+ students of bone marrow stem cells,” says Hoggatt. “Finding that they express genes similar to those of fetal liver HSCs, the blood-producing cells you have before birth, suggests that they will be very good at moving into an empty bone marrow space and rapidly dividing to fill the marrow and produce blood. Now we need to test the combination in a clinical trial to confirm its safety and effectiveness in humans.”
A principal faculty member at the Harvard Stem Cell Institute and an assistant professor of Medicine at Harvard Medical School, Hoggatt adds that these new, highly engraftable HSCs and the protocol that generated them represent a valuable new scientific tool that could lead to ways of engineering cells that are even better at engrafting and to methods of expanding stem cells in the laboratory rather than within the bodies of donors.
“This is an exciting time in bone marrow transplantation, as the number of diseases that can be treated or possibly even cured is increasing,” he says. “With new gene therapy strategies being developed for diseases like sickle cell anemia, beta thalassemia and severe combined immunodeficiency – the ‘bubble boy disease’ – having enough high-quality, gene-altered cells can be a key bottleneck. Our ability to acquire highly engraftable HSCs with the GRO-beta and AMD3100 combination should significantly improve and expand the availability of those treatments.”
[/et_pb_text][et_pb_team_member admin_label=”Person” image_url=”https://medicineinnovates.com/wp-content/uploads/2018/01/Jonathan-Hoggatt-Medicine-Innovates.jpg” animation=”off” background_layout=”light” header_font_size=”22″ use_border_color=”off” border_color=”#ffffff” border_width=”1px” border_style=”solid” disabled=”off”]
Jonathan Hoggatt holds appointments in both the Cancer Center and Center for Transplantation Sciences. He is also a principal faculty member of the Harvard Stem Cell Institute and a principal faculty member of the Stem Cell and Regenerative Biology Department at Harvard University.
Jon obtained his PhD from Indiana University School of Medicine in 2010, where his dissertation was recognized as the most outstanding amongst all disciplines and awarded the Esther L. Kinsley award. He then completed a post-doctoral fellowship with David Scadden at Harvard University, where he received an HSCI T32 training award, and an NIH Pathway to Independence award.
Jon’s work over the last several years has focused on translational science in bone marrow transplantation, and has resulted in several clinical trials and high profile papers in Nature, Nature Medicine, and others. During his graduate studies, Jon served as a Police Commissioner and then later as a City Councilman for West Lafayette, Indiana. He currently serves the American Society of Hematology on the Government Affairs and Communications Committees and is a Contributing Editor of The Hematologist.
[/et_pb_team_member][et_pb_team_member admin_label=”Person” image_url=”https://medicineinnovates.com/wp-content/uploads/2018/01/Louis-Pelus-Medicine-Innovates.jpg.jpg” animation=”off” background_layout=”light” header_font_size=”22″ use_border_color=”off” border_color=”#ffffff” border_style=”solid” disabled=”off”]
PhD, Professor of Microbiology & Immunology at Indiana University School of Medicine.
His research interest in identifying mechanisms of action of stem cell mobilizers that will lead to safer and faster isolation of blood stem cells that can be used to cure leukemia and other cancers; to understand the role of the inhibitor of apoptosis family of proteins in normal and cancer biology.
Dr. Pelus’ laboratory is interested in the mechanisms that control blood cell proliferation, differentiation and migration, and how these pathways can be leveraged to define new therapies for leukemia and cancer
[/et_pb_team_member][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”justified” use_border_color=”off” border_style=”solid” disabled=”off” border_color=”#ffffff”]
Hoggatt J, Singh P, Tate TA, Chou BK, Datari SR, Fukuda S, Liu L, Kharchenko PV, Schajnovitz A, Baryawno N, Mercier FE, Boyer J, Gardner J, Morrow DM, Scadden DT, Pelus LM. Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell. Cell. 2017 Nov 17. pii: S0092-8674(17)31312-0. doi: 10.1016/j.cell.2017.11.003Go To Cell